OSU 6162 hydrochlorideDopamine stabilizer CAS# 156907-84-5 |
- PDK1 inhibitor
Catalog No.:BCC1843
CAS No.:1001409-50-2
- GSK2334470
Catalog No.:BCC4982
CAS No.:1227911-45-6
- Radicicol
Catalog No.:BCC2131
CAS No.:12772-57-5
- BX-912
Catalog No.:BCC1250
CAS No.:702674-56-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 156907-84-5 | SDF | Download SDF |
PubChem ID | 9836644 | Appearance | Powder |
Formula | C15H24ClNO2S | M.Wt | 317.87 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | PNU 96391 | ||
Solubility | Soluble to 100 mM in water and to 100 mM in DMSO | ||
Chemical Name | (3S)-3-(3-methylsulfonylphenyl)-1-propylpiperidine;hydrochloride | ||
SMILES | CCCN1CCCC(C1)C2=CC(=CC=C2)S(=O)(=O)C.Cl | ||
Standard InChIKey | LEMGVHZVBREXAD-PFEQFJNWSA-N | ||
Standard InChI | InChI=1S/C15H23NO2S.ClH/c1-3-9-16-10-5-7-14(12-16)13-6-4-8-15(11-13)19(2,17)18;/h4,6,8,11,14H,3,5,7,9-10,12H2,1-2H3;1H/t14-;/m1./s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Dopamine stabilizer; lacks high affinity for various neuroreceptors in vitro (Ki values are 447 and 1305 nM for D2 and D3 receptors respectively and > 1 μM for other targets). Exhibits high D2 receptor occupancy in vivo; highly active on dopamine synthesis and turnover. Induces stabilizing effects on psychomotor function in behavioral tests without inducing hypolocomotion or catalepsy. |
OSU 6162 hydrochloride Dilution Calculator
OSU 6162 hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.1459 mL | 15.7297 mL | 31.4594 mL | 62.9188 mL | 78.6485 mL |
5 mM | 0.6292 mL | 3.1459 mL | 6.2919 mL | 12.5838 mL | 15.7297 mL |
10 mM | 0.3146 mL | 1.573 mL | 3.1459 mL | 6.2919 mL | 7.8649 mL |
50 mM | 0.0629 mL | 0.3146 mL | 0.6292 mL | 1.2584 mL | 1.573 mL |
100 mM | 0.0315 mL | 0.1573 mL | 0.3146 mL | 0.6292 mL | 0.7865 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Licofelone
Catalog No.:BCC4432
CAS No.:156897-06-2
- N1,N11-Diethylnorspermine tetrahydrochloride
Catalog No.:BCC6654
CAS No.:156886-85-0
- Ibuprofen
Catalog No.:BCC3791
CAS No.:15687-27-1
- Cephalexin
Catalog No.:BCC4646
CAS No.:15686-71-2
- Hosenkoside A
Catalog No.:BCN4962
CAS No.:156791-82-1
- Iristectorene B
Catalog No.:BCN7695
CAS No.:156791-81-0
- Agroastragaloside I
Catalog No.:BCC8294
CAS No.:156769-94-7
- 3-beta-Hydroxyergost-5-en-7-one
Catalog No.:BCN1704
CAS No.:156767-69-0
- Hosenkoside C
Catalog No.:BCN2632
CAS No.:156764-83-9
- Hosenkoside B
Catalog No.:BCN4584
CAS No.:156764-82-8
- (RS)-(±)-Sulpiride
Catalog No.:BCC6835
CAS No.:15676-16-1
- Delphinidin-3-O-rutinoside chloride
Catalog No.:BCN3115
CAS No.:15674-58-5
- Isosalicifolin
Catalog No.:BCN6502
CAS No.:156974-99-1
- Grosvenorin
Catalog No.:BCN1262
CAS No.:156980-60-8
- Wedeliatrilolactone A
Catalog No.:BCN6732
CAS No.:156993-29-2
- H-D-Arg-OH
Catalog No.:BCC2868
CAS No.:157-06-2
- 5,7-Dihydroxy-3,4',8-trimethoxyflavone
Catalog No.:BCN1551
CAS No.:1570-09-8
- U 89843A
Catalog No.:BCC7466
CAS No.:157013-85-9
- SNAP 5089
Catalog No.:BCC7350
CAS No.:157066-77-8
- Lipedoside B-III
Catalog No.:BCC8201
CAS No.:157085-48-8
- 3-Amino-4-hydroxybenzoic acid
Catalog No.:BCC8610
CAS No.:1571-72-8
- Ajuforrestin A
Catalog No.:BCN8008
CAS No.:157110-18-4
- Noopept
Catalog No.:BCC1804
CAS No.:157115-85-0
- Harzianic acid
Catalog No.:BCN1838
CAS No.:157148-06-6
The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat.[Pubmed:16648369]
J Pharmacol Exp Ther. 2006 Aug;318(2):810-8.
"Dopamine stabilizers" are a new class of compounds that have the ability to reverse both hypo- as well as hyperdopaminergia in vivo. This class, exemplified by the phenylpiperidines (S)-(-)-3-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonyl-phenyl)-1-propyl)-piperidine [ACR16] although lacking high in vitro binding affinity for dopamine D2 receptor [(-)-OSU6162, Ki = 447 nM; ACR16, Ki > 1 microM], shows functional actions, suggestive of their interaction. Hence, we evaluated in vivo D2 occupancy of these agents in rats and correlated it to observed effects in a series of behavioral, neurochemical, and endocrine models relevant to the dopamine system and antipsychotic effect. Both (-)-OSU6162 and ACR16 showed robust dose-dependent striatal D2 occupancy with ED50 values of 5.27 and 18.99 mg/kg s.c., respectively, and functional assays showed no partial agonism. Over an occupancy range of 37 to 87% (3-60 mg/kg) for (-)-OSU6162 and 35 to 74% (10-60 mg/kg) for ACR16, we observed both inhibitory (amphetamine-induced locomotor activity) and stimulatory effects (in habituated rats). Haloperidol, over a similar occupancy range (33-78%), potently inhibited psychostimulant activity and induced catalepsy, but it failed to activate habituated animals. In the conditioned avoidance response assay, ACR16 was clearly more efficacious than (-)-OSU6162. In addition, both these compounds demonstrated significant preferential Fos induction in the nucleus accumbens compared with the dorsolateral striatum, a strong predictor of atypical antipsychotic efficacy. The results suggest that dopamine stabilizers exhibit locomotor stabilizing as well as antipsychotic-like effects, with low motor side effect liability, in a dose range that corresponds to high D2 in vivo occupancy.
PNU-96391A (OSU6162) antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson's disease.[Pubmed:12384167]
Neuropharmacology. 2002 Oct;43(5):817-24.
PNU-96391A is a weak dopamine (DA) D(2) receptor antagonist with behavioral stabilizing properties. Previous experiments revealed that PNU-96391A antagonizes the expression of L-DOPA induced behavioral sensitization (dyskinesias) in lesioned primates without inducing akinesia or reducing the anti-Parkinsonian efficacy of L-DOPA. This study evaluated the ability of PNU-96391A to block the development of DA agonist-induced behavioral sensitization in rats with unilateral 6-OH-DA lesions of the median forebrain bundle. Repeated twice daily treatment with L-DOPA and the decarboxylase inhibitor benserazide (15 and 5 mg/kg, IP, respectively), or quinpirole (D(2)/D(3) agonist, 0.1 mg/kg, SC) increased the contralateral rotations measured on day 7 and 14 as compared to day 1. PNU-96391A (10-60 mg/kg, SC, bid.) antagonized the development of behavioral sensitization induced by both agonists. The basal activity of L-DOPA was not affected while a reduction of quinpirole-induced rotations was observed after 30-60 mg/kg, SC of PNU-96391A. Neurochemical analyses confirmed >99 % reductions of striatal DA levels, unilaterally. Concomitant treatment with PNU-96391A and L-DOPA did not affect plasma levels of PNU-96391A indicating that the effects observed are not related to pharmacokinetic interactions. These results suggest that PNU-96391A could be therapeutically useful to prevent the development of behavioral sensitization induced by DA agonists.